2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
Target:
MMP-9
In Vivo
MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor[1]. MMP-9-IN-1 inhibits cancer cell metastasis in vivo[1]. Animal Model: 4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor[1] Dosage: 20 mg/kg Administration: Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks, Result: Resulted in a profound delay in tumor growth. Inhibited cancer cell metastasis.
In Vitro
MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity[1]. MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells[1]. Cell Cytotoxicity Assay[1] Cell Line: COS-1 monkey epithelial cell lines Concentration: 100 μM Incubation Time: 24 hours Result: Treatment did not cause notable cytotoxicity. Cell Proliferation Assay[1] Cell Line: HT-1080 and MDA-MB-435 cancer cells expressing endogenous MMP-9 Concentration: 10 μM Incubation Time: 9 days Result: Significant inhibition of cell proliferation.
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Dufour A, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011 Jul 15;71(14):4977-88.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
